CRL vs IQV
CRL: Charles River Laboratories is a global, non-clinical contract research organization that partners with life sciences companies to streamline drug discovery and development. IQV: IQVIA is a global leader in clinical research and healthcare data analytics that powers the development and commercialization of life-saving medical treatments.
Side-by-side fundamentals
| Metric | CRL | IQV | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $298.00 | $258.88 | |
| Market cap | $14.2B | $43.2B | |
| P/E as of 2026-10-08 | n/a | 32.10 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 2.90 | |
| Net margin FY2025, SEC XBRL | -3.6% | +8.3% | IQV higher |
| Operating margin FY2025, SEC XBRL | +0.6% | +13.4% | IQV higher |
| ROE FY2025, SEC XBRL | -4.6% | +20.5% | IQV higher |
| ROA FY2025, SEC XBRL | -2.0% | +4.5% | IQV higher |
| Debt / equity as of 2026-09-03 | 0.93 | 2.59 | CRL lower |
| Revenue growth (YoY) as of 2026-09-03 | -0.7% | +8.2% | IQV higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | +4.2% | IQV higher |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | IQV higher |
| Beta as of 2026-09-03 | 1.37 | 0.97 | |
| 1-year return as of 2026-10-08 close | +71.8% | +29.1% | CRL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.